XAIR Stock Forecast & Price Target

Beyond Air Inc. demonstrated robust financial growth in the quarter ended June 30, 2025, with revenue reaching $1.8 million, reflecting a remarkable 157% increase compared to the prior year, primarily driven by heightened demand for its LungFit PH system. The company also achieved a positive gross profit of $0.2 million, marking a pivotal shift in its financial trajectory from a gross loss of $0.3 million in the same quarter last year. Additionally, Beyond Air is enhancing its commercial presence through strategic partnerships, including a national group purchasing agreement with Premier, Inc., which expands its access to over 4,350 hospitals and health systems across the U.S. and establishes a strong international footprint reaching approximately 2.8 billion people.

Beyond Air Inc. has reported a gross loss reduction to $0.3 million from $1.1 million year-over-year; however, the company continues to face significant financial challenges, with a net loss of $7.9 million, or $1.25 per share. Despite a decrease in research and development expenses to $2.5 million from $4.6 million, the net cash burn of $4.7 million raises concerns about the sustainability of the business model in a competitive landscape. Additionally, the company's therapeutic approach, particularly the potential adverse effects of Nitric Oxide on cellular respiration and tumor microenvironments, introduces further skepticism regarding the efficacy and safety of its product offerings.